Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01767766 · ClinicalTrials.gov registry record · Phase 1
Evaluate the Safety and Efficacy of TGR 1202 in Patients With Relapsed or Refractory Hematologic Malignancies
A Phase 1 study, sponsored by TG Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 90
- Enrollment target
NCT01767766 is a Phase 1 study that has completed, run by TG Therapeutics. The registered enrollment target is 90 participants.
The verdict
NCT01767766, a Phase 1 study, has completed, sponsored by TG Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 90 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and effectiveness of TGR-1202 in patients with advanced hematologic malignancies.
Interventions
- DRUG TGR-1202
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2013-01-07 |
| Est. Completion | 2018-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01767766
The ClinicalTrials.gov registry entry for NCT01767766 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is TG Therapeutics, which has 33 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which TGR-1202 is the first listed.
NCT01767766 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01767766 about?
NCT01767766 is a clinical study titled "Evaluate the Safety and Efficacy of TGR 1202 in Patients With Relapsed or Refractory Hematologic Malignancies". The purpose of this study is to evaluate the safety and effectiveness of TGR-1202 in patients with advanced hematologic malignancies.
What is the current status of trial NCT01767766?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 90 participants. The study started on 2013-01-07. Estimated completion is 2018-02.
What interventions are being tested in trial NCT01767766?
The interventions under investigation include: TGR-1202 (DRUG).
Who is sponsoring clinical trial NCT01767766?
This trial is sponsored by TG Therapeutics, which has 33 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.